Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Fazirsiran in Subjects With or Without Hepatic Impairment
NCT05891158Phase 1Completed
- Sponsor
- Takeda
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 2
01
Overview
Phase 1, open-label trial of fazirsiran in liver failure (4 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration at Month 6, Area Under the Plasma Concentration-time Curve from Time 0 to Infinity at Month 6 and 1 more. Started Oct 2023; status: completed.
02
Drugs
fazirsiran
03
Conditions
liver failure
Beyond the preview
Go deeper on NCT05891158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891158.